Search Results - "FRENAY, M"

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force by Soffietti, R., Baumert, B.G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang-Xuan, K., Klein, M., Melin, B., Rees, J., Siegal, T., Smits, A., Stupp, R., Wick, W.

“…Background:  Diffuse infiltrative low‐grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological and…”
Get full text

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF by Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., Schott, R., Honnorat, J., Fabbro, M., Tennevet, I., Ghiringhelli, F., Guillamo, J.S., Durando, X., Castera, D., Frenay, M., Campello, C., Dalban, C., Skrzypski, J., Chinot, O.

“…Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation. Activity of bevacizumab (BEV) and irinotecan (IRI)…”
Get full text

Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971 by VAN DEN BENT, M. J, TAPHOORN, M. J. B, ALLGEIER, A, GORLIA, T, BRANDES, A. A, MENTEN, J, STUPP, R, FRENAY, M, CHINOT, O, KROS, J. M, VAN DER RIJT, C. C. D, VECHT, Ch. J

“…Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy with procarbazine, lomustine, and…”
Get full text

Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group by HOANG-XUAN, K, TAILLANDIER, L, CHINOT, O, SOUBEYRAN, P, BOGDHAN, U, HILDEBRAND, J, FRENAY, M, DE BEULE, N, DELATTRE, J. Y, BARON, B

“…To assess the efficacy and toxicity of chemotherapy alone in patients older than 60 years with primary CNS lymphoma. Fifty patients with a median age of 72…”
Get full text

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group by Stupp, R., Tosoni, A., Bromberg, J.E.C., Hau, P., Campone, M., Gijtenbeek, J., Frenay, M., Breimer, L., Wiesinger, H., Allgeier, A., van den Bent, M.J., Bogdahn, U., van der Graaf, W., Yun, H.J., Gorlia, T., Lacombe, D., Brandes, A.A.

“…Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood–brain barrier has demonstrated preclinical activity in glioma…”
Get full text

Difficulties in diagnosing terminal ileitis due to Yersinia pseudotuberculosis by Wunderink, H. F., Oostvogel, P. M., Frénay, I. H. M. E., Notermans, D. W., Fruth, A., Kuijper, E. J.

“…We report three patients with terminal ileitis and positive fecal cultures with Yersinia pseudotuberculosis . From one patient, a virulence plasmid…”
Get full text

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas by TRIEBELS, V. H. J. M, TAPHOORN, M. J. B, VAN HEUVEL, I, VAN DEN BENT, M. J, BRANDES, A. A, MENTEN, J, FRENAY, M, TOSONI, A, KROS, J. M, BIEMOND-TER STEGE, E, ENTING, R. H, ALLGEIER, A

“…The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in…”
Get full text

First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas by Frenay, M. P., Fontaine, D., Vandenbos, F., Lebrun, C.

“…At the present time, there are no proven beneficial effects of chemotherapy (CT) for the treatment of pure low‐grade astrocytomas. Brain radiotherapy (RT)…”
Get full text

Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy by Lebrun, C., Fontaine, D., Bourg, V., Ramaioli, A., Chanalet, S., Vandenbos, F., Lonjon, M., Fauchon, F., Paquis, P., Frenay, M.

“…Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure…”
Get full text

Unattainable educational goals: Disengagement, reengagement with alternative goals, and consequences for subjective well-being by Boudrenghien, G, Frenay, M, Bourgeois, É

“…Abstract Introduction Is it always positive, in terms of well-being, to be highly committed to one's goals? Even if giving up on goals is most often seen as an…”
Get full text

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics by Julian-Reynier, Claire, Bouhnik, Anne-Déborah, Mouret-Fourme, Emanuelle, Gauthier-Villars, Marion, Berthet, Pascaline, Lasset, Christine, Fricker, Jean-Pierre, Caron, Olivier, Gesta, Paul, Luporsi, Elisabeth, Faivre, Laurence, Longy, Michel, Gladieff, Laurence, Frenay, Marc, Dreyfus, Héléne, Sobol, Hagay, Vennin, Philippe, Nogués, Catherine

“…To investigate the medical and psychosocial factors determining the time to prophylactic surgery of unaffected women carriers of a deleterious BRCA1/2…”
Get full text

Long-term outcome of oligodendrogliomas by LEBRUN, C, FONTAINE, D, FRENAY, M, RAMAIOLI, A, VANDENBOS, F, CHANALET, S, LONJON, M, MICHIELS, J. F, BOURG, V, PAQUIS, P, CHATEL, M

“…Favorable prognostic factors for oligodendroglial tumors include age younger than 40 years, low tumor grade, and extent of resection. To assess survival time…”
Get full text

Nitroso-urea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity by Bourg, V., Lebrun, C., Chichmanian, R. M., Thomas, P., Frenay, M.

“…Background: The incidence of haematologic toxicity of valproate (VPA) ranges from l% to 32%, and consists mainly of asymptomatic, dose-dependent thrombopenia…”
Get full text

Neurologic side effects of cytotoxic drugs by Lebrun, C, Frenay, M

“…Damage to the nervous system is a common side effect of antineoplastic therapy. The improvements in treating systemic malignancies have been accompanied by the…”
Get full text

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma by RAYMOND, E, FABBRO, M, VERMILLET, L, ARMAND, J. P, BOIGE, V, RIXE, O, FRENAY, M, VASSAL, G, FAIVRE, S, SICARD, E, GERMA, C, RODIER, J. M

“…To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma…”
Get full text

Primitive cerebral melanoma: A diagnostic and management challenge. About 2 cases by Mondot, L, Almairac, F, Vandenbos, F, Fontaine, D, Frenay, M, Chanalet, S

“…Summary In this report of two cases of solitary cerebral meningeal melanoma, a rare tumor that presents both diagnostic and management challenges, the…”
Get full text

Turcot syndrome confirmed with molecular analysis by Lebrun, C., Olschwang, S., Jeannin, S., Vandenbos, F., Sobol, H., Frenay, M.

“…Turcot syndrome is clinically characterized by the occurrence of primary brain tumor and colorectal tumor and has, in previous reports, been shown associated…”
Get full text

Genetic diseases and glioblastomas by Almairac, F, Frenay, M, Paquis, P

“…Some cancers are involved in inherited genetic syndromes. These genetic diseases are suspected of being involved in approximately 1% of gliomas. Few data are…”
Get full text

Bevacizumab for the treatment of cerebral radionecrosis by Gronier, S, Bourg, V, Frenay, M, Cohen, M, Mondot, L, Thomas, P, Lebrun, C

“…Bevacizumab is a monoclonal antibody, which neutralizes the effect of vascular endothelium growth factor (VEGF) allowing regression of tumour vessels and a…”
Get full text

Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma by Belpomme, D., Gauthier, S., Pujade-Lauraine, E., Facchini, T., Goudier, M.-J., Krakowski, I., Netter-Pinon, G., Frenay, M., Gousset, C., Marié, F. N., Benmiloud, M., Sturtz, F.

“…Background Verapamil (VER), a potent calcium channel blocker, has been found to overcome P-gp-mediated multidrug resistance (MDR) and to increase sensitivity…”
Get full text